NovaBridge Biosciences Unveils Promising Clinical Trial Data and Strategic Rebranding

Clinical-stage biopharmaceutical company NovaBridge Biosciences, formerly known as I-Mab, has released compelling updated Phase 1 data for its bispecific antibody candidate, givastomig. The complete dataset was presented in late October at the AACR-NCI-EORTC international conference, highlighting the drug’s performance in treating heavily pre-treated gastric cancer patients.

Givastomig, a CLDN18.2 x 4-1BB bispecific antibody, demonstrated an objective response rate of 18% in this challenging patient population. The disease control rate reached a notable 49%, with median progression-free survival recorded at 2.96 months and median overall survival at 7.49 months.

A significant finding from the trial reveals that treatment efficacy was consistent across various dose levels and CLDN18.2 expression thresholds. Researchers observed no new Read more...